Zydus Cadila receives tentative approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Zydus Cadila receives tentative approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets Ahmedabad, 25 March, 2021 Zydus Cadila has received tentative approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg (US RLD: TRUVADA® Tablets). Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are used with other HIV medications to help control HIV infection. This product is a combination of two different drugs: Emtricitabine and Tenofovir Disoproxil Fumarate and helps to decrease the amount of HIV in the body so that the immune system can work better. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. ***

The release as fetched from its publisher. zyduslife.com ↗